IQV IQVIA Holdings Inc

IQVIA Forms Alliance with Box to Provide Revolutionary, Cloud-Based Content Management Solutions to the Life Sciences and Healthcare Industries

IQVIA™ (NYSE: IQV), a company dedicated to using analytics and science to help healthcare stakeholders find better solutions for patients, today announced at the eyeforpharma conference that it has entered into an alliance with Box, a leading cloud content management platform provider. The Box platform expands and strengthens IQVIA’s Platform of Platforms strategy by adding standardized content management, complementing our existing partnerships with Salesforce, Amazon Web Services and other leading platforms.

With the enhanced content management capabilities this alliance provides, IQVIA’s life sciences customers will be able to work with an ever expanding range of content and mobile devices, without disrupting any services they already use. The Box platform also helps clients protect against security threats and supports client efforts to manage complex compliance requirements, including the European Union’s General Data Protection Regulation.

“We’re excited to welcome an innovative company such as IQVIA into the Box Technology Partner Program,” said Riju Khetarpal, managing director, Global Life Sciences at Box. “With the IQVIA collaboration, our joint customers will be able to seamlessly address the unique and complex challenges of managing content within the life sciences industry.”

Under the agreement, IQVIA will build its suite of integrated, intelligent, and easy-to-use applications to manage regulated and non-regulated content for life sciences customers on Box’s modern, cloud-based content collaboration platform. These content-driven applications help clients manage complex workflows, increase global visibility and reuse of content, and apply appropriate security, and data retention polices throughout the product lifecycle.

“Our alliance with Box shows our commitment to developing innovative technology solutions built on an integrated Platform of Platforms strategy,” said Tal Rosenberg, senior vice president, Global Technology Solutions, IQVIA. “This allows our customers to maintain the flexibility to work with best-in-class providers like Box, which is an innovative, high-growth organization that will help us deliver industry-first technologies for efficiently managing content from R&D through commercial to our customers around the world.”

IQVIA introduced its Platform of Platforms strategy in April 2017 when it announced an alliance with Salesforce. Through this strategy, IQVIA builds its life science specific solutions on top of technology platforms, many of which are already part of customers’ ecosystems. This approach enables the company to focus on areas of differentiation and delivering greater value to life sciences and healthcare customers in the form of transformative technology solutions.

For more information on the IQVIA/Box collaboration, please visit Exhibit 38-42 at the eyeforpharma Barcelona conference, or email [email protected].

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on helping healthcare clients find better solutions for patients. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation, and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps their customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.IQVIA.com.

Click here to subscribe to Mobile Alerts for IQVIA.

EN
14/03/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IQVIA Holdings Inc

IQVIA Holdings Inc: 1 director

A director at IQVIA Holdings Inc sold 1,300 shares at 246.330USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

Moody's assigns Baa3 rating to IQVIA's new senior secured notes, Ba2 r...

Moody's Investors Service (Moody's) assigned Baa3 rating to the proposed US dollar-denominated senior secured notes, and Ba2 rating to the proposed senior unsecured notes of IQVIA Inc. ("IQVIA"). There are no changes to IQVIA's existing ratings, including the Ba1 corporate family rating (CFR), Ba1-P...

IQVIA HOLDINGS sees a downgrade to Slightly Negative on account of les...

The independent financial analyst theScreener just lowered the general evaluation of IQVIA HOLDINGS (US), active in the Health Care Providers industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date January 18, 2022, the closing price was US...

Valens Research
  • Valens Research

Valens Equity Insights and Inflections - 2021 12 07

Freeport-McMoRan (FCX) is one of the best-positioned copper miners to benefit from the various megatrends pushing copper demand higher. Uniform Accounting highlights that the market is significantly mispricing the value of Freeport's production capabilities, signaling the potential for equity upside. With trends like the IoT and EVs driving stronger demand for precious metals, copper producers like Freeport are well positioned for a boost in profitability. Additionally, Freeport has the po...

Valens Research
  • Valens Research

IQV - Embedded Expectations Analysis - 2021 12 02

IQVIA Holdings (IQV) currently trades above corporate and historical averages relative to Uniform earnings, with a 28.2x Uniform P/E (Fwd. V/E'). At these levels, markets are pricing in expectations for Uniform ROA to recover to 62%, accompanied by 12% Uniform asset growth. Similarly, analysts expect Uniform ROA to improve to 58% by 2022, accompanied by 24% Uniform asset growth. If sustained going forward, these levels would imply a stock price closer to $414, representing significant potenti...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch